Literature DB >> 35419174

Does Drug Holiday Affect Jaw Trabeculation in Medication Related Osteonecrosis of the Jaw? - A Pilot Study.

Niranzena Panneer-Selvam1, Abrar Alamoudi2, Joseph Riley Iii3, Joseph Katz4.   

Abstract

Background: The role of drug holiday in long term antiresorptive drug users to prevent MRONJ is debated for quite some time. We aimed to compare jawbone trabeculation between patients on drug holiday with those not on drug holiday among Medication Related Osteonecrosis of the Jaw (MRONJ) cases using fractal analysis and to estimate the frequency of MRONJ despite being on drug holiday. Material and
Methods: The sample of 18 MRONJ cases were divided into drug holiday, and non-drug holiday groups. Non-drug holiday group was further divided into pre- and post- drug holiday groups. Jawbone trabeculation was assessed utilizing fractal analysis method (ImageJ software) by two observers. ANOVA was used to compare the fractal dimension (FD) values between the groups. A 'p' value of less than 0.05 was considered significant.
Results: 8 patients developed MRONJ despite being on drug holiday (44.44%). There was no significant difference in the FD values between drug holiday and pre-drug holiday groups. When pre- and post-drug holiday FD values were compared, the difference was significant only on the right maxilla with observer 2. Also, no significant difference was noted between the two observers. Conclusions: Bone trabeculation remained unaltered following drug holiday from anti-resorptive drugs. This study serves as a preliminary proof for the argument against drug holiday which portrays the necessity for a detailed prospective study in this arena. Key words:Osteonecrosis, bisphosphonates, Bisphosphonate-Associated Osteonecrosis of the Jaw, anti-resorptive drugs, osteoporosis, jaw. Copyright:
© 2022 Medicina Oral S.L.

Entities:  

Year:  2022        PMID: 35419174      PMCID: PMC9000388          DOI: 10.4317/jced.59503

Source DB:  PubMed          Journal:  J Clin Exp Dent        ISSN: 1989-5488


  22 in total

1.  The reliability of cone-beam computed tomography to assess bone density at dental implant recipient sites: a histomorphometric analysis by micro-CT.

Authors:  Raúl González-García; Florencio Monje
Journal:  Clin Oral Implants Res       Date:  2012-01-17       Impact factor: 5.977

2.  Prolonged bisphosphonate release after treatment in children.

Authors:  Socrates E Papapoulos; Serge C L M Cremers
Journal:  N Engl J Med       Date:  2007-03-08       Impact factor: 91.245

3.  Tooth extractions in intravenous bisphosphonate-treated patients: a refined protocol.

Authors:  Matteo Scoletta; Valentina Arata; Paolo G Arduino; Ennio Lerda; Andrea Chiecchio; Giorgia Gallesio; Crispian Scully; Marco Mozzati
Journal:  J Oral Maxillofac Surg       Date:  2013-02-21       Impact factor: 1.895

4.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

5.  Osteonecrosis of the jaws associated with denosumab: Study of clinical and radiographic characteristics in a series of clinical cases.

Authors:  Victoria I Tofé; Leticia Bagán; José V Bagán
Journal:  J Clin Exp Dent       Date:  2020-07-01

6.  Osteonecrosis of the Jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS).

Authors:  Xiaoyan Zhang; Issam S Hamadeh; Shuang Song; Joseph Katz; Jan S Moreb; Taimour Y Langaee; Lawrence J Lesko; Yan Gong
Journal:  J Bone Miner Res       Date:  2015-09-04       Impact factor: 6.741

7.  The relationship of denosumab pharmacology and osteonecrosis of the jaws.

Authors:  John Malan; Kyle Ettinger; Erich Naumann; O Ross Beirne
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol       Date:  2012-12

8.  Fracture risk remains reduced one year after discontinuation of risedronate.

Authors:  N B Watts; A Chines; W P Olszynski; C D McKeever; M R McClung; X Zhou; A Grauer
Journal:  Osteoporos Int       Date:  2007-10-16       Impact factor: 4.507

Review 9.  Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus.

Authors:  Aliya A Khan; Archie Morrison; David A Hanley; Dieter Felsenberg; Laurie K McCauley; Felice O'Ryan; Ian R Reid; Salvatore L Ruggiero; Akira Taguchi; Sotirios Tetradis; Nelson B Watts; Maria Luisa Brandi; Edmund Peters; Teresa Guise; Richard Eastell; Angela M Cheung; Suzanne N Morin; Basel Masri; Cyrus Cooper; Sarah L Morgan; Barbara Obermayer-Pietsch; Bente L Langdahl; Rana Al Dabagh; K Shawn Davison; David L Kendler; George K Sándor; Robert G Josse; Mohit Bhandari; Mohamed El Rabbany; Dominique D Pierroz; Riad Sulimani; Deborah P Saunders; Jacques P Brown; Juliet Compston
Journal:  J Bone Miner Res       Date:  2015-01       Impact factor: 6.741

10.  American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update.

Authors:  Salvatore L Ruggiero; Thomas B Dodson; John Fantasia; Reginald Goodday; Tara Aghaloo; Bhoomi Mehrotra; Felice O'Ryan
Journal:  J Oral Maxillofac Surg       Date:  2014-05-05       Impact factor: 2.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.